LifeMD (LFMD) Cash & Equivalents (2012 - 2025)

LifeMD's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $36.8 million for Q4 2025.

• Quarterly Cash & Equivalents rose 12.7% year-over-year to $36.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.8 million (up 12.7% YoY) and the FY2025 annual result came in at $36.8 million, up 12.7% from the prior year.
• Cash & Equivalents was $36.8 million for Q4 2025 at LifeMD, up from $23.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $41.3 million in Q4 2021 and bottomed at $4.0 million in Q4 2022.
• A 5-year average of $23.9 million and a median of $25.1 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 3646.16% — and 2022, when it tumbled 90.42%.
• LifeMD's Cash & Equivalents stood at $41.3 million in 2021, then tumbled by 90.42% to $4.0 million in 2022, then jumped by 737.26% to $33.1 million in 2023, then retreated by 1.49% to $32.7 million in 2024, then grew by 12.7% to $36.8 million in 2025.
• Business Quant data shows LFMD's Cash & Equivalents at $36.8 million in Q4 2025, $23.8 million in Q3 2025, and $36.2 million in Q2 2025.